# Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

> **NCT00292396** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 180 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Anti IL-12 monoclonal antibody/ABT-874
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00292396
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2013-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00292396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00292396, "Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00292396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*